Global Biosimulation Market (2022 Edition) – Analysis By Component (Software, Service), Application (Drug Discovery, Pre-Clinical, Clinical), End-User, By Region, By Country: Market Insights and Forecast (2018-2028)

Global Biosimulation Market (2022 Edition) – Analysis By Component (Software, Service), Application (Drug Discovery, Pre-Clinical, Clinical), End-User, By Region, By Country: Market Insights and Forecast (2018-2028)

Executive Summary

According to a research report published by Azoth Analytics in November 2022, the Global Biosimulation Market was valued at USD 3011.50 Million in the year 2021. Biosimulation helps to increase the probability of success in human clinical trials, the most expensive part of drug development. Biosimulation helps to optimize dosing for different populations for enhanced safety and efficacy. New drugs can cause significant increases in retail spending because they are more expensive, in high demand, or both. Currently, In-Silico methods are outpacing various stages of drug discovery, particularly in biomedicine sciences.

Biosimulation drug discovery offers numerous opportunities for error elimination through computer simulation, which can improve drug performance and accuracy. In the forthcoming years, there will be more potential for the Biosimulation market to flourish due to the expanding applications and rising use of personalized medicine and biosimulation solutions for the development of paediatric drugs. Companies around the world use key strategies such as Component launches, business expansions, mergers and acquisitions, patents and approvals, agreements and collaborations.

The key software methods for developing a drug are structure-based drug design, molecular modelling, structure-based virtual screening, ligand interaction, and molecular dynamics. New technologies such as virtual reality and artificial intelligence (AI) are expanding the opportunities for drug discovery. Americas has the lucrative growth in the Biosimulation industry and the United States remains the country with the earliest launches accounting for 72 NASs launched in 2021.

Scope of the Report

• The report presents the analysis of the Biosimulation market for the historical period of 2018-2021, the estimated year 2022 and the forecast period of 2023-2028.
• The report analyses the Biosimulation Market by Value (USD Million).
• The report analyses the Biosimulation Market by Component (Software, Service)
• The report analyses the Biosimulation Market by Application (Drug Discovery, Pre-Clinical, Clinical)
• The report analyses the Biosimulation Market by End-User (Academic & Government Research Institutes, Pharmaceutical & Biotech Companies, Contract Research Organization, Regulatory Authorities)
• The Global Biosimulation Market has been analysed by countries (United States, Canada, Mexico, Germany, United Kingdom, France, Italy, China, Japan, India)
• The attractiveness of the market has been presented by region, by Component, Application and End-User.
• Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include – Certara, Inc., Simulations Plus, Inc., Schrödinger, Inc., Dassault Systèmes, Physiomics plc, Thermo Fisher Scientific, Instem plc, Advanced Chemistry Development, Inc., Chemical Computing Group, Optibrium

• Pharmaceutical and Healthcare Companies
• Pharmaceutical Research and Development Companies
• Consulting and Advisory Firms
• Government and Policy Makers
• Regulatory Authorities